S&P Futures
3,653.50+30.25(+0.83%)Dow Futures
29,858.00+229.00(+0.77%)Nasdaq Futures
12,377.75+100.75(+0.82%)
Qualigen Therapeutics, Inc. (QLGN)
- Zacks Small Cap Research
QLGN: Testing AS1411 as COVID-19 Treatment…
By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update AS1411 Clinical Trial in COVID-19 to Initiate 1H21 On October 28, 2020, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced a positive pre-IND meeting with the U.S. FDA regarding the development of AS1411 as a treatment for COVID-19. AS1411 is a DNA aptamer that has exhibited antiviral activity in a number of
- PR Newswire
Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that Michael Poirier, President, Chief Executive Officer and Chairman, has issued a letter to Qualigen's stockholders. The full text is as follows:
- PR Newswire
Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced today it has signed a contract with STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of WuXi AppTec, for GMP production of AS1411, Qualigen's lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials. Preclinical studies at the University of Louisville's (UofL) Center for Infectious Disease have demonstrated the ability of AS1411, a novel aptamer-based molecule, to protect cells from the damaging effects of the novel coronavirus.
